Who Paid My Doc Search
Menu
Organisation paid for research Program year 2024 Source: CMS Open Payments

Minnesota Lung Center

Neither a doctor nor a teaching hospital

Research payments

$1,922,763

292 payments

Through program year 2024, Minnesota Lung Center is reported as receiving $1,922,763 in research payments, across 292 payments.

By program year

6 rows
Year Kind Amount Payments
2024 Research $123,542 16
2023 Research $233,827 5
2022 Research $257,478 19
2021 Research $397,248 65
2020 Research $451,196 88
2019 Research $459,473 99

Breakdown

Who paid Research payments · program years 2019–2024
  1. GlaxoSmithKline, LLC. $443,369 49 payments
  2. Galvanize Therapeutics, Inc $421,240 10 payments
  3. Merck Sharp & Dohme Corporation $257,559 82 payments
  4. Shionogi Inc $223,139 45 payments
  5. Jazz Pharmaceuticals Inc. $163,506 49 payments
  6. Novartis Pharmaceuticals Corporation $145,512 11 payments
  7. AstraZeneca Pharmaceuticals LP $79,065 11 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $72,903 11 payments
  9. Bayer HealthCare Pharmaceuticals Inc. $71,888 15 payments
  10. Harmony Biosciences LLC $33,694 4 payments
Studies the money was for Research payments · program years 2019–2024
  1. CS006 RheOx Pivotal $421,240 10 payments
  2. A Randomized, Adaptive, Double-Blind, Placebo-Controlled, Parallel-Arm $237,043 22 payments
  3. Evaluation of S-600918 in Adults With Refractory Chronic Cough $223,139 45 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-MonthStudy to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with ChronicCough PN030 $165,272 49 payments
  5. A Phase IV, 12-Week, Randomised, Double-Blind, Triple Dummy Study to C $156,057 6 payments
  6. A 24 Week Multicenter Double Blind Placebo Controlled Dose Ranging Study to Investigate the Efficacy and Safety of Oral Qbw251 in COPD Patients on Triple Therapy (Laba/Lama/Ics) $145,512 11 payments
  7. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 12-Month Study to Evaluate the Efficacy and Safety of MK-7264 in Adult Participants with Chronic Cough PN030 $89,057 15 payments
  8. A Phase 4 Multicenter Open-Label Single-Arm Study of Safety Tolerability Effectiveness and Treatment Optimization in Participants Switching From Xyrem to Xywav for the Treatment of Narcolepsy $72,020 2 payments
  9. Randomized double-blind parallel group Phase 2b dose-finding efficacy and safety study of 12-week twice daily oral administration of BAY 1817080 compared to placebo in the treatment of refractory and/or unexplained chronic cough (RUCC) $71,888 15 payments
  10. Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) $67,392 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2024

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record